Fewer Bacterial Relapses after Oral Treatment with Norfloxacin than with Ceftibuten in Acute Pyelonephritis Initially Treated with Intravenous Cefuroxime
| Autor: | Hans G. Boman, Stig Cronberg, Mats Hugo-Persson, Eva Johansson, Bo Bergman, Anders Lindblom, Peter Wieslander, Nils Kuylenstierna, Elisabeth Elbel, Otto Paulsen, Staffan Banke, Peter Lanbeck, Mats Walder, Tönnes Eilard, Christer Schönbeck |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty medicine.drug_class Urinary system Antibiotics Administration Oral Gastroenterology Anti-Infective Agents Double-Blind Method Recurrence Oral administration Internal medicine Escherichia coli medicine Humans Ceftibuten Prospective Studies Escherichia coli Infections Norfloxacin Aged Antibacterial agent Aged 80 and over Cefuroxime Pyelonephritis General Immunology and Microbiology business.industry General Medicine Bacteriological Cure Middle Aged Cephalosporins Surgery Treatment Outcome Infectious Diseases Acute Disease Injections Intravenous Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Scandinavian Journal of Infectious Diseases. 33:339-343 |
| ISSN: | 1651-1980 0036-5548 |
| DOI: | 10.1080/003655401750173922 |
| Popis: | This double-blind, multicentre study was performed at nine centres on a total of 171 patients who presented with fever (38.5 degrees C) and signs of acute pyelonephritis. All were initially treated with intravenous cefuroxime. After 2-3 d, when the fever had subsided and urinary culture had revealed growth of Gram-negative bacteria (10(7) colony-forming units per litre), treatment was changed to oral administration of ceftibuten 200 mg b.i.d. or norfloxacin 400 mg b.i.d. for 10 d. The patients were followed for signs of bacterial or clinical relapse 7-14 d after the end of treatment. The initial clinical and bacteriological cure was excellent in both groups, but there were significantly fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute febrile pyelonephritis initially treated with intravenous cefuroxime. The causal strain was eradicated in 75% of patients (73% of males, 76% of females) in the ceftibuten group and in 89% of patients (94% of males, 85% of females) in the norfloxacin group. The relative frequency of eradication was 0.84 (p0.05; 95%, confidence interval 0.74-0.97). Adverse events were reported by 47% of the patients in the ceftibuten group and by 38% in the norfloxacin group. This difference was not significant, but diarrhoea or loose stools occurred more frequently in the ceftibuten group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|